isirv Antiviral Group
AVG Home
|
AVG Webinar Series
Webinar 2 on Antiviral Resistance took place on Tuesday 24 January and you can listen to the recording via this link. There were 4 talks covering SARS-CoV-2, flu and RSV. The coronavirus helicase contributes to remdesivir resistance but impairs virus fitness and helicase function – Professor Mark Denison, Vanderbilt University Medical Center, Nashville, TN, USA SARS-CoV-2 resistance to antibodies and protease inhibitors - Dr Emi Takashita, National Institute of Infectious Diseases, Tokyo, Japan Influenza A virus polymerase acidic protein E23G/K substitutions weaken key baloxavir drug-binding contacts with minimal impact on replication and transmission - Dr Jeremy Jones, St. Jude Children’s Research Hospital, Memphis TN, USA Monoclonal antibodies and promising antivirals for RSV – the challenges - Professor Tony Piedra, Baylor College of Medicine, Houston, TX, USA Future webinars: 25 April – ‘The Present and Future of Treatment Oriented Surveillance’ ** Unfortunately we’ve had to reschedule this webinar to 20 June at the following time: 8.30am ET/ 1.30pm UK/ 2.30pm CET/ 9.30pm CST ** Keep an eye out for dates of subsequent webinars in this series.
7th AVG Conference (in-person)
Visit the conference website here
Recent Virtual Conference
AVG Overview
The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv. Its specific objectives are to promote understanding of the clinical use of antivirals against respiratory viruses, collate and provide up to date information on the emergence of antiviral resistance, and communicate expert commentary on preclinical and clinical development of potential novel/new antivirals. Read More
Recent AVG Events Therapeutics for COVID-19, a special virtual conference, 6-8 October 2020
The 3-day programme addressed the latest advances in the development of antivirals and other therapeutics for use against COVID-19 and possibilities for improved clinical management. Oral and e-poster presentations are available. Read more
AVG Polymerase Inhibitor Resistance Meeting, at the Offices of the Task Force for Global Health, Atlanta, USA, 7-8 August 2019
The participants at this small specialist meeting, including public health, academic and corporate representatives who are conducting studies on the new antivirals targeting the influenza RNA polymerase, met to discuss the impact of resistance to these inhibitors. A report of the meeting is incorporated in an Assessment of the Current State of the Art report published in Antiviral Research and now on the AVR journal web site as a highlighted article. Read more
Antiviral News
Latest… Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials... read more Influenza antivirals and their role in pandemic preparedness... read more An optimized cell-based assay to assess influenza virus replication by measuring neuraminidase activity and its applications for virological surveillance... read more Endonuclease and other Polymerase Inhibitors
Antiviral Susceptibilities of Distinct Lineages of Influenza C and D Viruses... read more
New Drug Discovery
Preclinical Study of ZSP1273, a Potent Antiviral Inhibitor of Cap Binding to the PB2 Subunit of Influenza A Polymerase... read more
Clinical Trials & Case Studies
Investigating the transmission of baloxavir-resistant influenza viruses from treated index patients to untreated household contacts in the BLOCKSTONE study... read more
Novel modelling approaches to predict the role of antivirals in reducing influenza transmission...read more
|
Visit us on:
  Quick links:
Contact AVG:Email:avg@isirv.org |
